adamantane has been researched along with sorafenib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, AA; Bruzek, LM; Carter, CA; Gores, GJ; Kaufmann, SH; Meng, XW; Yu, C | 1 |
| Beljanski, V; Knaak, C; Smith, CD; Zhuang, Y | 1 |
| Beljanski, V; Lewis, CS; Smith, CD | 1 |
| Baar, K; Carraway, KL; Gilda, JE; Gomes, AV; Hammock, BD; Hwang, SH; Leon, LJ; Patton, A; Wecksler, AT; Weiss, RH; Wettersten, HI | 1 |
| Amore, E; Azzolina, A; Balasus, D; Bondì, ML; Botto, C; Cervello, M; Mazzaglia, A; Scala, A; Sortino, G | 1 |
| Boakye, J; Chaiteerakij, R; Chen, G; Ding, X; Huang, S; Li, Y; Moser, CD; Ndzengue, A; Roberts, LR; Shaleh, H; Sinicrope, FA; Smith, CD; Thomas, MB; Zhou, Y; Zou, X | 1 |
6 other study(ies) available for adamantane and sorafenib
| Article | Year |
|---|---|
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
Topics: Adamantane; Apoptosis; Base Sequence; Benzenesulfonates; Caspases; Cell Line, Tumor; DNA Primers; Down-Regulation; Enzyme Activation; Humans; Hydroquinones; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2005 |
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
Topics: Adamantane; Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Caspase 3; Caspase 7; Catechols; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Humans; Kidney Neoplasms; Mice; Mice, SCID; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Flow Cytometry; Hep G2 Cells; Humans; Liver Neoplasms; Lysophospholipids; Mice; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Sphingosine; Xenograft Model Antitumor Assays | 2011 |
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Autophagy; Benzamides; Caspases; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mitochondrial Membranes; Niacinamide; Oxidative Stress; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sorafenib; Urea | 2014 |
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells.
Topics: Adamantane; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Survival; Cyclodextrins; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Erythrocytes; Hemolysis; Hepatocytes; Humans; Kinetics; Nanostructures; Niacinamide; Phenylurea Compounds; Sorafenib; Surface-Active Agents | 2015 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Cells, Cultured | 2016 |